Subject: vaccine | RC109-216 | HIV | challenges | Infectious and parasitic diseases | Article
mesheuropmc: viruses | virus diseases
The road to the discovery of a vaccine for HIV has been arduous and will continue to be difficult over the ensuing twenty years. Most vaccines are developed by inducing neutralizing antibodies against the target pathogen or by using attenuated strains of the particular ... View more
1. Baba T.W., Liska V., Hofmann-Lehmann R. et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000; 6:200-206.
2. Mascola J.R., Stiegler G., VanCott T.C. et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000; 6:207-210.
3. Parren P.W., Marx P.A., Hessell A.J. et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/ human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001; 75:8340-8347.
4. Allen T.M., Jing P., Calore B. et al. Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection. J Virol 2002; 76:10507-10511.
5. Allen T.M., Mortara L., Mothe B.R. et al. Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication. J Virol 2002; 76:4108-4112.
6. Vogel T.U., Reynolds M.R., Fuller D.H. et al. Multispecific vaccineinduced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239. J Virol 2003; 77:13348- 13360.
8. Kirchhoff F., Pohlmann S., Hamacher M. et al. Simian immunodeficiency virus variants with differential T-cell and macrophage tropism use CCR5 and an unidentified cofactor expressed in CEMx174 cells for efficient entry. J Virol 1997; 71:6509-6516.
9. Chen Z., Zhou P., Ho D.D., Landau N.R., and Marx P.A. Genetically divergent strains of simian immunodeficiency virus use CCR5 as a coreceptor for entry. J Virol 1997; 71:2705-2714.
10. Chen Z., Gettie A., Ho D.D., and Marx P.A. Primary SIVsm isolates use the CCR5 coreceptor from sooty mangabeys naturally infected in west Africa: a comparison of coreceptor usage of primary SIVsm, HIV-2, and SIVmac. Virology 1998; 246:113- 124.